On October 22, 2026, the Cancer of the Pancreas Screening-5 (CAPS5) Study, registered as NCT02000089, was listed with a status of recruiting. The trial is designated as Phase 3. Secretin, an approved compound, is involved in this study. The study title and current status were confirmed as of the listed date. No results or outcomes data have been reported for this trial at this time. The trial status reflects recruitment activity only and does not indicate findings about safety or effectiveness. Secretin remains an approved compound, and this update pertains solely to trial recruitment status. Readers interested in additional information about this clinical trial can consult the official registry listing. For general background on secretin, including its approved uses and regulatory status, readers can refer to the compound overview.
Secretin Trial Update: CAPS5 Study (NCT02000089) Status Recruiting
See the full secretin overview
Source: https://clinicaltrials.gov/study/NCT02000089